Advertisements

Фамопсин

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Фамопсин

What is Фамопсин?

Фамопсин is a pharmaceutical product containing the active ingredient famotidine. It belongs to a class of medications known as histamine H2-receptor antagonists (or H2 blockers). This medication is primarily used to manage conditions related to the overproduction of gastric acid.

Mechanism of Action

The digestive process involves the secretion of acid by parietal cells in the stomach lining. Histamine plays a key role in stimulating these cells to produce acid. Фамопсин works by competitively inhibiting the H2 receptors located on these parietal cells. By blocking these receptors, the medication reduces both the volume and the concentration of gastric acid secreted under various conditions, including:

  • Basal acid secretion: The acid produced continuously, even when the stomach is empty.
  • Nocturnal acid secretion: Acid produced during the night.
  • Stimulated acid secretion: Acid production triggered by food, caffeine, or certain physiological stimuli.

Therapeutic Purpose

By lowering the acidity levels in the stomach, Фамопсин helps create an environment conducive to the healing of the mucous membranes. It is typically utilized in the context of acid-related gastrointestinal disorders where reducing gastric juice acidity is necessary to alleviate discomfort or promote the recovery of the digestive tract lining.

Unlike antacids, which neutralize existing acid in the stomach, Фамопсин acts at the source of production, providing a more prolonged effect on acid suppression. It is distinct from proton pump inhibitors (PPIs) in its specific chemical pathway, though both classes of drugs aim to reduce stomach acid levels.

Regulatory References

  1. NIH/PubMed
  2. MedlinePlus
Advertisements

What side effects are possible with Фамопсин?

Possible Side Effects and Safety Information

The safety profile of Фамопсин, whose active component is Famotidine, is documented by government regulatory agencies and classified by frequency and body system. This systematic approach establishes the official understanding of the medicine's risk profile.


Official Adverse Reaction Classification

Adverse reactions are grouped according to their observed incidence in clinical use, which allows for standardized safety communication:

  • Common Reactions: Reactions reported most frequently include headache, dizziness, constipation, and diarrhoea.
  • Uncommon Reactions: Less frequent reactions include nausea, vomiting, abdominal discomfort, rash, and fatigue.
  • Rare Reactions: Infrequently reported but clinically significant reactions involve systems like the blood and lymphatic system, nervous system, and immune system. These include blood dyscrasias (e.g., thrombocytopenia), severe hypersensitivity reactions (e.g., anaphylaxis), and cholestatic jaundice.

System-Organ Classes and Serious Events

Side effects are categorized by the physiological system they affect, aligning with regulatory standards (System-Organ-Classes or SOCs). While common effects primarily relate to the Nervous and Gastrointestinal systems, rare but serious adverse reactions, such as agranulocytosis or severe bullous skin reactions, are also documented in the official labeling.


Population-Specific Safety Considerations

The official prescribing information notes specific safety considerations related to patient demographics and physiological state.

  • Older Adults and Renal Impairment: Patients who are elderly or who have renal impairment are noted for an increased potential risk for psychiatric disturbances, such as confusion or hallucinations, due to changes in drug clearance.
  • Safety Restrictions: Caution is advised regarding the use of Famotidine in patients with severe hepatic or renal impairment, as well as in situations where a gastric malignancy has not been excluded, since symptom relief does not rule out the presence of a tumor.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile for Фамопсин by listing specific documented clinical manifestations and required emergency actions. Treatment is symptomatic and supportive, as no specific antidote is known.

Documented Clinical Presentation

Overdose exposure may present with a range of effects across the central nervous, cardiovascular, and gastrointestinal systems. Documented symptoms include headache, dizziness, somnolence, confusion, agitation, and low blood pressure. Gastrointestinal disturbances such as nausea, vomiting, diarrhea, or constipation are also noted.

Severe Outcomes and Emergency Actions

Regulatory information identifies Grand mal seizures, QT prolongation, Atrioventricular (AV) block, and difficulty breathing as potential severe systemic outcomes. Immediate medical help must be sought if a suspected overdose occurs. According to official labeling, urgent medical attention is required when the patient has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Contacting a Poison Control Center right away is also mandated.

Management and Specific Considerations

Treatment procedures include the removal of unabsorbed material from the gastrointestinal tract and subsequent clinical monitoring. The regulatory documentation notes that patients with impaired renal function have an increased risk of experiencing severe reactions, including the potential for cardiac and neurological effects.

Advertisements

Therapeutic Uses of Фамопсин

What Фамопсин Treats: Main Uses and Benefits

Фамопсин (Famotidine) provides therapeutic support by managing symptoms related to heightened physiological activity across domains involving inflammatory or irritative processes in the gastrointestinal tract. This assistance is relevant in contexts marked by increased discomfort and is part of appropriate supportive symptom management.

Quick Fact: Support for Symptoms of Acid-Related Irritation


Support for Symptom Manifestations of Heartburn and Indigestion

This medication is commonly used to help address symptom clusters that may appear suddenly, such as heartburn and acid indigestion. It helps address the burning sensation and symptoms that may interfere with daily functioning, offering supportive relief during acute, episodic manifestations.

Support for Healing and Ulcer Management

Beyond addressing acute symptoms, Фамопсин is relevant in conditions presenting with systemic or localized discomfort, such as active gastric and duodenal ulcers and erosive esophagitis. It may assist in the management of pain associated with these irritative states, which contributes to easing the overall symptom load during periods of heightened symptoms.

Role in Prevention and Long-Term Stability

It is considered relevant in the symptomatic management associated with reducing the potential for ulcer recurrence, particularly following the healing of duodenal ulcers. It is also applied in situations where additional management of discomfort is required, such as preventing gastric injury associated with certain medications, providing support that helps ease the overall symptom burden and may assist with maintaining a sense of stability.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Фамопсин — official regulatory information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults under standard labeled conditions.
  • Pediatric Oral Use for children weighing 40 kg or more.
  • Pediatric IV Use for hospitalized patients 1 year of age and older.

Populations for whom use is not recommended (if applicable):

  • Pregnant Individuals: Generally not recommended unless use is clearly necessary (EMA/MHRA guidance).
  • Breastfeeding Mothers: Not recommended, as the drug is excreted in human breast milk, with official guidance advising to discontinue either the drug or nursing.

Populations for whom use is contraindicated:

  • Patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or any other Histamine H₂-receptor antagonist (H₂-blockers).

Condition-specific eligibility rules:

  • Severe Renal Impairment: Requires dosage reduction in adults with moderate to severe renal impairment (creatinine clearance < 50 mL/min or < 60 mL/min) to prevent drug accumulation and potential CNS reactions.
  • Gastric Malignancy: Symptomatic relief does not preclude the presence of gastric malignancy; evaluation for cancer should be considered prior to starting therapy for gastric ulcers.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

  • Contraindicated: Hypersensitivity to H₂-blockers.
  • Use Not Established: Safety and efficacy have not been established for pediatric patients with renal impairment.
  • Dose Modification Required: Adults with moderate to severe renal impairment.

Connection to the overall eligibility profile (2–4 sentences): The official eligibility profile establishes an absolute prohibition for individuals with known H₂-blocker hypersensitivity. Beyond this, regulatory documents define specific limitations based on the patient's age, such as minimum thresholds for pediatric use, and physiological status. These established rules classify the populations for whom use is allowed, restricted, or explicitly not recommended, strictly according to regulatory standards.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Фамопсин (Famotidine) is defined by two primary pharmacokinetic mechanisms documented in regulatory sources.

Gastric pH-Dependent Interactions (Reduced Exposure)

Famotidine's acid-reducing action elevates gastric pH, which significantly reduces the systemic exposure and effectiveness of medicinal products that require an acidic stomach environment for absorption. This exposure reduction applies to several drug classes, including certain Tyrosine Kinase Inhibitors (e.g., Erlotinib, Acalabrutinib), Antifungals (e.g., Ketoconazole, Itraconazole), and Iron Supplements (Ferrous Salts). Regulatory documentation establishes mandatory timing separation rules for co-administration with pH-sensitive drugs like Erlotinib (must be separated by 2 hours before or 10 hours after) to manage this interaction.

Metabolic and Clearance Interactions (Increased Exposure)

Famotidine is a weak inhibitor of the CYP1A2 isoenzyme. This effect can substantially increase the blood concentrations of co-administered CYP1A2 substrate drugs, such as Tizanidine, leading to increased risk. Due to this risk, regulatory prescribing information advises avoiding concomitant use of Famotidine with Tizanidine. Additionally, in patients with moderate or severe renal impairment or in the elderly, slower clearance of Famotidine prolongs its elimination, which increases the susceptibility to CNS adverse outcomes during co-administration assessments.

Advertisements

Mechanism of Action

How Фамопсин Works: Mechanism of Action

Фамопсин (Famotidine) works through a pharmacodynamic mechanism focused on modulating gastric acid secretion.

Blocking the Histamine Signal (H2-Receptor Antagonism)

Фамопсин functions as a competitive antagonist at the Histamine H2 receptors located on the parietal cells of the gastric lining. This selective molecular action blocks histamine—a primary chemical messenger for acid production—from binding to the receptor and initiating its stimulus.

Interrupting the Intracellular Cascade

The receptor blockade interrupts the subsequent signal transduction within the cell. This action prevents the usual increase in intracellular cyclic AMP (cAMP), thereby reducing the phosphorylation and mobilization of the final acid-secreting enzyme. This reduces the activity of the H^+/ K^+-ATPase (Proton Pump), the membrane enzyme responsible for transporting acid into the stomach lumen.

️ Modulating Gastric Acidity Homeostasis

By suppressing the activation of the proton pump, the drug's mechanism leads to a reduction in the overall volume and concentration of hydrochloric acid released by the parietal cells. This system-level physiological effect modulates the gastric acidity system by producing a measurable consequence of higher pH (lower acidity) within the stomach.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Famotidine (Фамопсин)

This section outlines the usage instructions for Famotidine, the active substance in Фамопсин.

1. Administration Scope and Route

Famotidine is administered via the Oral (PO) route using tablets or liquid suspension, or the Intravenous (IV) route using an injection solution.

Administration Method Standard Dosing Regimen Timing and Schedule
Oral (PO) 20 mg twice daily OR 40 mg once daily. Maintenance is 20 mg once daily. May be taken with or without food. Once-daily dosing is often taken at bedtime.
Intravenous (IV) 20 mg every 12 hours. Administered in a medical setting, typically over 15 to 30 minutes via infusion.

2. Preparation and Procedural Rules

  • Oral Suspension: The container must be shaken thoroughly before measuring and administering the dose.
  • IV Administration: The injection solution must be diluted before use, usually with 0.9% Sodium Chloride Injection, and administered slowly over a period of not less than 2 minutes for slow injection, or over 15 to 30 minutes for infusion.

3. Population-Specific Instructions

  • Renal Impairment: Dosage and frequency must be adjusted for patients with severe kidney problems (creatinine clearance less than 50 mL/min). The dose interval may be extended (e.g., every 36 to 48 hours) or the dose reduced.
  • Geriatric Use: Dosing should be approached cautiously, often starting at the lower end of the dosing range.
Advertisements

Recent Clinical Evidence

Famotidine: Recent Clinical Evidence

Famotidine, a histamine H2-receptor antagonist, is primarily studied and approved for its role in suppressing gastric acid secretion. This action is the basis for its long-established use in treating and preventing conditions such as duodenal and gastric ulcers, Gastroesophageal Reflux Disease (GERD), and pathological hypersecretory conditions (e.g., Zollinger–Ellison syndrome).


Established Efficacy Data

The efficacy of Famotidine in acid-related disorders is supported by numerous randomized controlled trials (RCTs). Research has evaluated its dose-dependent effect on inhibiting basal, nocturnal, and stimulated gastric acid output. A typical duration of antisecretory activity observed in studies is 10 to 12 hours following administration, which is a key factor for its use in maintenance therapy.


Areas of Ongoing Research

While its use in gastrointestinal conditions is well-defined, recent clinical research has explored potential applications outside of acid suppression, with studies primarily focusing on its anti-inflammatory potential. Current research and trials have investigated the drug's activity in the following areas:

  • COVID-19: Several retrospective analyses and outpatient RCTs have been conducted to assess whether Famotidine is associated with reduced inflammation and changes in the clinical course for patients with mild-to-moderate disease. Findings from these studies have been mixed, suggesting the need for further definitive, large-scale trials.
  • Other Indications: Exploratory studies have examined the potential use of Famotidine as an adjunctive treatment in certain neurological conditions, such as levodopa-induced dyskinesia in Parkinson's disease, though evidence remains limited and is not considered definitive.

Safety Profile in Specific Populations

Research has consistently noted that the elimination half-life of Famotidine can be prolonged nonlinearly in patients with moderate to severe renal impairment. This observation suggests that dose adjustments may be necessary for these patients to mitigate the potential for increased systemic exposure and adverse effects.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Фамопсин (FAQ)


Q: Is Фамопсин classified as an anti-inflammatory drug?

A: Famotidine is officially classified as a Histamine H2-receptor antagonist (H2-blocker), which means its primary action is reducing the production of stomach acid. It is not currently classified as an anti-inflammatory medicine for standard clinical use. Studies have explored its potential anti-inflammatory effects in specific conditions, but this is considered an area of ongoing research.


Q: What is the standard time frame for Фамопсин to show its effects?

A: According to official regulatory information, the therapeutic effect of reducing stomach acid typically begins within one hour after taking an oral dose of Famotidine. The maximum, strongest effect of the drug is generally observed within one to three hours after administration.


Q: What should I do if I experience mild dizziness from Фамопсин?

A: Dizziness is listed in the official prescribing information as a common side effect reported with Famotidine use. Because this content cannot offer personal medical guidance, if you have any persistent or concerning symptoms, such as dizziness, seeking guidance from a qualified healthcare provider is appropriate.


Q: Is it generally safe to drive or operate machinery after taking Фамопсин?

A: The official product information advises caution regarding activities requiring mental alertness, such as driving or operating machinery. This is due to the potential for central nervous system side effects like dizziness and confusion. A patient's ability to drive or operate machinery may be affected, so exercising caution until the individual effect of the medication is known is suggested.


Q: Is there any evidence for the use of Фамопсин in older populations (seniors)?

A: Studies cited in regulatory documents indicate that there was no overall increase in the incidence or type of side effects in older adults compared to younger patients. No dose adjustment is required for patients solely based on age. However, caution is advised when Famotidine is used in seniors who also have kidney impairment.


Q: How does the body eliminate Фамопсин from the system?

A: Official pharmacological data indicates that Famotidine is eliminated from the body primarily through the kidneys. About 65% to 70% of the dose is removed in the urine as the unchanged compound. This is the basis for required dose adjustments for those with kidney problems.


Q: Is Фамопсин known to cause changes in mood or anxiety levels?

A: Regulatory documents report that rare, serious side effects include certain mood or mental changes, such as anxiety, agitation, confusion, and depression. These psychiatric disturbances are noted to occur more often in older adults or patients with existing kidney disease.


Q: Is it true that Фамопсин is related to older classes of medications?

A: Famotidine belongs to a specific family of drugs known as Histamine H2-receptor antagonists (or H2-blockers). This class of medications has been used to treat acid-related conditions for many years. The official contraindications acknowledge this link by advising against its use in patients sensitive to any other drug in the H2-blocker class.


Q: What is the shelf life of Фамопсин tablets?

A: Regulatory stability studies have supported a shelf life of 3 years for the Famotidine tablet formulation. Maintaining product effectiveness depends on storing the tablets according to the instructions, such as being protected from moisture and light, as indicated in the documentation.


Q: Does Фамопсин interact with common herbal remedies?

A: Official regulatory advice notes the importance of informing a healthcare provider about all substances being taken, including herbal remedies and supplements. Although specific interactions with every herb may not be listed, this is suggested because potential risks need to be medically evaluated.


Q: Does Фамопсин require any special diet restrictions beyond what is on the label?

A: Famotidine tablets can be taken either with or without food. While the drug itself does not impose strict diet restrictions, official guidance refers to avoiding certain foods, such as rich, spicy, fatty foods, chocolate, and caffeine, as these items are known to trigger heartburn symptoms.


Q: What happens if a person accidentally takes two tablets of Фамопсин?

A: Regulatory information stresses that patients should follow the prescribed dose and should not take more medicine than ordered. If an individual takes an amount exceeding the prescribed dose, official documents specify contacting a healthcare professional or Poison Control Center for guidance.


Q: Does Фамопсин interact with commonly used over-the-counter cold and flu medications?

A: Interactions with over-the-counter (OTC) cold and flu products can vary greatly depending on the specific ingredients they contain. Official regulatory instruction notes the importance of disclosing all over-the-counter medicines to a healthcare provider for a thorough review.


Q: How long is a typical course of treatment with Фамопсин?

A: The length of a typical treatment course with Famotidine depends entirely on the condition being addressed. For example, treating an active duodenal ulcer may take up to 8 weeks, while the duration for over-the-counter use is generally limited to 14 days.


Q: Are there different versions or generic brands of Фамопсин?

A: Famotidine is the internationally recognized active ingredient and is available in various forms, including both prescription and over-the-counter (OTC) tablets. These formulations come in different strengths, such as 10 mg, 20 mg, and 40 mg.


Q: Is the long-term safety of Фамопсин described in regulatory documents?

A: Regulatory safety data is usually linked to the defined duration of treatment for the approved conditions. For certain conditions, such as active ulcers, data is typically available up to 8 weeks of treatment. Safety for long-term use is specifically addressed under the drug's approved maintenance therapy regimens.


Q: How is Фамопсин typically packaged and sold?

A: Official product information details that Famotidine is supplied in several different formats. These commonly include round, film-coated tablets in various strengths, as well as a liquid solution in single-dose or multi-dose vials for intravenous administration in a clinical setting.


Q: Does Фамопсин interact with caffeine?

A: While a direct drug-drug interaction is not specifically cited, official regulatory advice for managing heartburn includes avoiding certain beverages that can trigger symptoms. These beverages include caffeine and alcohol.


Q: Can Фамопсин be purchased without a doctor's prescription in some regions?

A: Famotidine is available in a dual status globally: it is sold both with a doctor's prescription (typically for higher doses or specific conditions) and as a lower-dose, over-the-counter (OTC) product.


Q: Does Фамопсин interact with common supplements like Vitamin C or Zinc?

A: Official regulatory advice notes the importance of informing a healthcare provider about all other supplements and vitamins being consumed. This is because any supplement, including Vitamin C or Zinc, could carry potential interaction risks that need professional evaluation.

Advertisements

How should Фамопсин be stored and disposed of?

Famotidine Storage and Disposal

The storage and disposal instructions for Famotidine (Фамопсин) are based on the official requirements for its different formulations, maintaining product stability and safety.


Required Storage Conditions

Famotidine Tablets must be stored at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), and must be protected from light and moisture. The unopened Injection Solution requires refrigeration, 2 C to 8 C (36 F to 46 F). All formulations must be protected from freezing and kept in the original container or a tight, light-resistant container.


Stability and Safety

Any unused reconstituted oral suspension must be discarded after 30 days. Famotidine must be kept out of the sight and reach of children.


Disposal Instructions

Unused or expired Famotidine must be disposed of in accordance with local requirements. The product should not be disposed of via wastewater or general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Фамопсин found in:

A-Z Index: